Matches in SemOpenAlex for { <https://semopenalex.org/work/W3031752474> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W3031752474 endingPage "442" @default.
- W3031752474 startingPage "439" @default.
- W3031752474 abstract "Objective To explore the relationship of plasma NT-proBNP level and severity of chronic congestive heart failure (CHF) and investigate the curative effect and security of meglumine adenosine cyclophosphate (MAC) combined with perindopril on patients with CHF.Methods From June 2011 to June 2013,126 inpatients with chronic congestive heart failure were randomly divided into A group (42 cases,routine therapy),B group (41 cases,routine therapy and perindopril) and C group (43 cases,routine therapy and perindopril plus MAC),all cases treated for 14 days.The left ventricular ejection fraction (LVEF) and left ventricular end-diastolic diameter (LVEDD) by echocardiography and plasma NT-proBNP levels were evaluated before and after 14 days therapy.Results The plasma NT-proBNP levels in NYHA Ⅱ ～ Ⅳ classes were significantly difference compared each other between any two classes (P ＜0.05) and the levels was positively correlated with NYHA cardiac function class and LVEDD (r =0.617,P ＜ 0.01 ; r =0.412,P ＜ 0.01),negatively correlated with LVEF (r =-0.372,P ＜ 0.01).After 14 days therapy,compared with A group,the LVEF and LVEDD significantly improved (P ＜ 0.05) and NT-proBNP level significantly decreased (P ＜ 0.05) in B,C groups; Compared with B group,C group had lower NT-proBNP level (P ＜ 0.05) although no further improvement in cardiac function.Conclusions The plasma NT-proBNP level is correlated closely with the severity of CHF and it is a good examination of diagnose,therapy and evaluating prognosis of CHF.Perindopril may significantly decline plasma NT-proBNP level and improve cardiac function of CHF patients,combined with MAC may further decline plasma NT-proBNP level although not further improved LVEF.Giving MAC and perindopril to patients with CHF was secure and patients tolerated it well.Key words: Melamine adenosine cyclophosphate; Perindopril; N-terminal pro-brain natriuretic peptide; Congestive heart failure" @default.
- W3031752474 created "2020-06-05" @default.
- W3031752474 creator A5007479338 @default.
- W3031752474 creator A5028295358 @default.
- W3031752474 creator A5049161336 @default.
- W3031752474 creator A5062697058 @default.
- W3031752474 creator A5081197970 @default.
- W3031752474 creator A5083035457 @default.
- W3031752474 date "2014-04-10" @default.
- W3031752474 modified "2023-09-23" @default.
- W3031752474 title "To evaluate the clinical curative effect of meglumine adenosine cyclophosphate combined with perindopril on patients with chronic congestive heart failure" @default.
- W3031752474 doi "https://doi.org/10.3760/cma.j.issn.1671-0282.2014.04.020" @default.
- W3031752474 hasPublicationYear "2014" @default.
- W3031752474 type Work @default.
- W3031752474 sameAs 3031752474 @default.
- W3031752474 citedByCount "0" @default.
- W3031752474 crossrefType "journal-article" @default.
- W3031752474 hasAuthorship W3031752474A5007479338 @default.
- W3031752474 hasAuthorship W3031752474A5028295358 @default.
- W3031752474 hasAuthorship W3031752474A5049161336 @default.
- W3031752474 hasAuthorship W3031752474A5062697058 @default.
- W3031752474 hasAuthorship W3031752474A5081197970 @default.
- W3031752474 hasAuthorship W3031752474A5083035457 @default.
- W3031752474 hasConcept C111566952 @default.
- W3031752474 hasConcept C126322002 @default.
- W3031752474 hasConcept C126838900 @default.
- W3031752474 hasConcept C143409427 @default.
- W3031752474 hasConcept C164705383 @default.
- W3031752474 hasConcept C2777843234 @default.
- W3031752474 hasConcept C2778198053 @default.
- W3031752474 hasConcept C2779200603 @default.
- W3031752474 hasConcept C71924100 @default.
- W3031752474 hasConcept C78085059 @default.
- W3031752474 hasConcept C84393581 @default.
- W3031752474 hasConceptScore W3031752474C111566952 @default.
- W3031752474 hasConceptScore W3031752474C126322002 @default.
- W3031752474 hasConceptScore W3031752474C126838900 @default.
- W3031752474 hasConceptScore W3031752474C143409427 @default.
- W3031752474 hasConceptScore W3031752474C164705383 @default.
- W3031752474 hasConceptScore W3031752474C2777843234 @default.
- W3031752474 hasConceptScore W3031752474C2778198053 @default.
- W3031752474 hasConceptScore W3031752474C2779200603 @default.
- W3031752474 hasConceptScore W3031752474C71924100 @default.
- W3031752474 hasConceptScore W3031752474C78085059 @default.
- W3031752474 hasConceptScore W3031752474C84393581 @default.
- W3031752474 hasIssue "04" @default.
- W3031752474 hasLocation W30317524741 @default.
- W3031752474 hasOpenAccess W3031752474 @default.
- W3031752474 hasPrimaryLocation W30317524741 @default.
- W3031752474 hasRelatedWork W1524350274 @default.
- W3031752474 hasRelatedWork W2235859217 @default.
- W3031752474 hasRelatedWork W2349099121 @default.
- W3031752474 hasRelatedWork W2349142954 @default.
- W3031752474 hasRelatedWork W2354772035 @default.
- W3031752474 hasRelatedWork W2356713682 @default.
- W3031752474 hasRelatedWork W2359294271 @default.
- W3031752474 hasRelatedWork W2360286923 @default.
- W3031752474 hasRelatedWork W2361936182 @default.
- W3031752474 hasRelatedWork W2371822852 @default.
- W3031752474 hasRelatedWork W2382449814 @default.
- W3031752474 hasRelatedWork W2390975228 @default.
- W3031752474 hasRelatedWork W2435554885 @default.
- W3031752474 hasRelatedWork W2510658295 @default.
- W3031752474 hasRelatedWork W2746046607 @default.
- W3031752474 hasRelatedWork W3031159945 @default.
- W3031752474 hasRelatedWork W3031483822 @default.
- W3031752474 hasRelatedWork W3032501110 @default.
- W3031752474 hasRelatedWork W3032536450 @default.
- W3031752474 hasRelatedWork W3032705430 @default.
- W3031752474 hasVolume "23" @default.
- W3031752474 isParatext "false" @default.
- W3031752474 isRetracted "false" @default.
- W3031752474 magId "3031752474" @default.
- W3031752474 workType "article" @default.